Skip to content
2000
Volume 5, Issue 4
  • ISSN: 1871-5281
  • E-ISSN: 2212-4055

Abstract

Hyaluronan (HA) is a variable length, long-chain polysaccharide containing repeating disaccharide units of glucuronic acid and n-acetylglucosamine. Long considered a relatively inert component of the extracellular matrix, HA is now coming under scrutiny as a potential therapeutic agent for a number of different diseases, based on its recently discovered role in modulating inflammation. The effect of HA on the inflammatory response appears to be related to its molecular size, with larger polysaccharide chains having anti-inflammatory activity and smaller ones having proinflammatory properties. This dichotomous behavior presents a challenge to investigators seeking to harness the beneficial effects of this molecule. Rapid breakdown of therapeutically administered HA into smaller fragments may conceivably cause further injury to diseased tissues. With this limitation in mind, the authors discuss their own use of HA to treat experimentally induced lung disease, then suggest possible ways of maximizing the therapeutic potential of this molecule.

Loading

Article metrics loading...

/content/journals/iadt/10.2174/187152806779010936
2006-12-01
2025-10-29
Loading full text...

Full text loading...

/content/journals/iadt/10.2174/187152806779010936
Loading

  • Article Type:
    Research Article
Keyword(s): emphysema; Hyaluronan; inflammation; lung
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test